

PUBLICATIONS AND PATENTS

Publications

Total number of publications: 168

Number of publications jointly authored between Divisions and Groups: 16

Cancer and Haematology Division

Primary

1. Alexander WS, Rakar S, Robb L, Farley A, Willson TA, Zhang J-G, Hartley L, Kikuchi Y, Kojima T, Nomura H, Hasegawa M, Maeda M, Fabri L, Jachno K, Nash A, Metcalf D, Nicola NA, Hilton DJ. Suckling defect in mice lacking the soluble haemopoietin receptor NR6. *Curr Biol* 9:605–608, 1999
2. Basser RL, To LB, Collins JP, Begley CG, Keefe D, Cebon J, Bashford J, Durrant S, Szer J, Kotasek D, Juttner C, Russell I, Maher DW, Olver I, Sheridan WP, Fox RM, Green MD. Multicycle high-dose chemotherapy and filgrastim-mobilized peripheral blood progenitor cells in women with high-risk stage II or stage III breast cancer: five year follow up. *J Clin Oncol* 17:82–92, 1999
3. Bennett DC, Trayner ID, Piao X, Easty DJ, Kluppel M, Alexander WS, Wagner EF, Bernstein A. Recessive spotting: a linked locus that interacts with W/Kit but is not allelic. *Genes Cells* 3:235–244, 1998
4. Bennett TM, Dowsing BJ, Austin L, Messina A, Nicola NA, Morrison WA. Anterograde transport of leukemia inhibitory factor within transected sciatic nerves. *Muscle Nerve* 22:78–87, 1999
5. Cambier N, Zhang Y, Vairo G, Kosmopoulos K, Metcalf D, Nicola NA, Elefanty AG. Expression of BCR – ABL in M1 myeloid leukemia cells induces differentiation without arresting proliferation. *Oncogene* 18:343–352, 1999
6. Dowsing BJ, Morrison WA, Nicola NA, Starkey GP, Bucci T, Kilpatrick TJ. Leukemia inhibitory factor is an autocrine survival factor for Schwann cells. *J Neurochem* 73:96–104, 1999
7. Elefanty AG, Begley CG, Metcalf D, Barnett L, Köntgen F, Robb L. Characterization of hematopoietic progenitor cells that express the transcription factor SCL, using a *lacZ* “knock-in” strategy. *Proc Natl Acad Sci U S A* 95:11897–11902, 1998
8. Fujita M, Norris DA, Walsh P, Morelli JG, Weston WL, Maxwell I, Terada N, Robinson WA, Lemon W, Yohn JJ. Overexpression of mutant N-RAS or H-RAS in human melanoma increases invasiveness and anchorage independent growth in vitro and induces tumor formation and cachexia in vivo. *J Invest Dermatol* (in press)
9. Gibbs P, Cebon JS, Calafiore P, Robinson WA. Cardiac metastases from malignant melanoma. *Cancer* 85:78–84, 1999
10. Gibbs P, Chen Q, Robinson WA. Effects of oncostatin M and tamoxifen on human melanoma cells. *Melanoma Res* 8:221–226, 1998
11. Grossman M, Metcalf D, Merryfull J, Beg A, Gerondakis S. The combined absence of the transcription factors Rel and RelA leads to multiple novel hemopoietic cell defects. *Proc Natl Acad Sci U S A* (in press)
12. Henry BA, Goding JW, Alexander WS, Tilbrook AJ, Canny BJ, Dunshea F, Rao A, Mansell A, Clarke IJ. Central administration of leptin to ovariectomized ewes inhibits food intake without affecting the secretion of hormones from the pituitary gland: evidence for a dissociation of effects on appetite and neuroendocrine function. *Endocrinology* 140:1175–1182, 1999
13. Kelly KA, Lucas K, Hochrein H, Metcalf D, Wu L, Shortman K. Development of dendritic cells in cultures from human and murine thymic precursor cells. *Cell Mol Biol* (in press)
14. Lah M, Brodnicki T, Maccarone P, Nash A, Stanley E, Harvey RP. Human cerberus related gene CER1 maps to chromosome 9. *Genomics* 55:364–366, 1999
15. Losman LA, Chen XP, Hilton DJ, Rothman P. Cutting edge: SOCS-1 is a potent inhibitor of IL-4 signal transduction. *J Immunol* 162:3770–3774, 1999
16. McManus JF, Begley CG, Sassa S, Ratnaike S. Three new mutations in the uroporphyrinogen decarboxylase gene in familial porphyria cutanea tarda. *Hum Mut* 13:412, 1999
17. Metcalf D, Alexander WS, Elefanty AG, Nicola NA, Hilton DJ, Starr R, Mifsud S, Di Rago L. Aberrant hematopoiesis in mice with inactivation of the gene encoding SOCS-1. *Leukemia* 13:926–934, 1999
18. Metcalf D, Nicola NA, Mifsud S, Di Rago L. Receptor clearance obscures the magnitude of granulocyte-macrophage colony stimulating factor responses in mice to endotoxin or local infections. *Blood* 93:1579–1585, 1999
19. Mitchell MS, Robinson WA, Buzaid W. Combined phase 2 trials of immunotherapy with melacine in the treatment of melanoma. *Melanoma Res* (in press)
20. Nicholson SE, Willson TA, Farley A, Starr R, Zhang JG, Baca M, Alexander WS, Metcalf D, Hilton DJ, Nicola NA. Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL-6 signal transduction. *Embo J* 18:375–385, 1999
21. Ogilvy S, Metcalf D, Gibson L, Bath ML, Harris AW, Adams JM. Promoter elements of *vav* drive transgene expression *in vivo* throughout the hematopoietic compartment. *Blood* 94:1855–1863, 1999
22. Piani A, Ilg T, Elefanty AG, Curtis J, Handman E. *Leishmania major* proteophosphoglycan is expressed by amastigotes and has an immunomodulatory effect on macrophage function. *Microbes Infect* (in press)
23. Print CG, Loveland KL, Gibson L, Meehan T, Stylianou A, Wreford N, de Kretser D, Metcalf D, Köntgen F, Adams JM, Cory S. Apoptosis regulator Bcl-w is essential for spermatogenesis but appears otherwise redundant. *Proc Natl Acad Sci U S A* 95:12424–12431, 1998
24. Robb L, Brodnicki T, Copeland NG, Gilbert DJ, Jenkins NA, Harvey RP. Assignment of the human helix-loop-helix transcription factor gene *musculin*/activated B-cell factor-1 (MSC) to chromosome 8q21 and its mouse homologue (*Msc*) to the proximal region of chromosome 1. *Genomics* 57:318–319, 1999
25. Robb L, Hartley L, Wang CC, Harvey RP, Begley CG. *musculin*: a murine basic helix-loop-helix transcription factor gene expressed in embryonic skeletal muscle. *Mech Dev* 76:197–201, 1998
26. Roberts MM, Swart BW, Simmons PJ, Basser RL, Begley CG, To LB. Prolonged release and c-kit expression of haemopoietic precursor cells mobilized by stem cell factor and granulocyte colony stimulating factor. *Br J Haematol* 104:778–784, 1999

27. Robinson WA, Lemon M, Elefanty A, Harrison-Smith M, Markham N, Norris D. Human acquired naevi are clonal. *Melanoma Res* 8:499–503, 1998
28. Scott CL, Hughes DA, Cary D, Nicola NA, Begley CG, Robb L. Functional analysis of mature hematopoietic cells from mice lacking the βc chain of the granulocyte-macrophage colony-stimulating factor receptor. *Blood* 92:4119–4127, 1998
29. Seymour JF, Begley CG, Dirksen U, Presneill JJ, Nicola NA, Moore PE, Schoch OD, van Asperen P, Roth B, Burdach S, Dunn AR. Attenuated hematopoietic response to granulocyte-macrophage colony-stimulating factor in patients with acquired pulmonary alveolar proteinosis. *Blood* 92:2657–2667, 1998
30. Stanley E, Biben C, Kotecha S, Fabri L, Tajbakhsh S, Wang CC, Hatzistavrou T, Roberts B, Drinkwater C, Lah M, Buckingham M, Hilton DJ, Nash A, Mohun T, Harvey RP. DAN is a secreted glycoprotein related to *Xenopus* cerberus. *Mech Dev* 77:173–184, 1998
31. Starr R, Metcalf D, Elefanty AG, Brysha M, Willson TA, Nicola NA, Hilton DJ, Alexander WS. Liver degeneration and lymphoid deficiencies in mice lacking suppressor of cytokine signaling-1. *Proc Natl Acad Sci U S A* 95:14395–14399, 1998
32. Wallack MK, Sivanandham M, Balch CM, Urist MM, Bland KI, Murray D, Robinson WA, Flaherty L, Richards JM, Bartolucci AA, Rosen L. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. *J Am Coll Surg* 187:69–77; discussion 77–79, 1998
33. Zhang J-G, Farley A, Nicholson SE, Willson TA, Zugaro LM, Simpson RJ, Moritz RL, Cary D, Richardson R, Hausmann G, Kile BJ, Kent SBH, Alexander WS, Metcalf D, Hilton DJ, Nicola NA, Baca M. The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. *Proc Natl Acad Sci U S A* 96:2071–2076, 1999
34. Zhang Y, Willson TA, Metcalf D, Cary D, Hilton DJ, Clark R, Nicola NA. The box-1 region of the leukemia inhibitory factor receptor α -chain cytoplasmic domain is sufficient for hemopoietic cell proliferation and differentiation. *J Biol Chem* 273:34370–34383, 1998

Reviews and books

35. Alexander WS. Thrombopoietin. *Growth Factors* 17:13–24, 1999
36. Alexander WS. Thrombopoietin and the c-Mpl receptor. *Int J Biochem Cell Biol* (in press)
37. Alexander WS, Starr R, Metcalf D, Nicholson SE, Farley A, Elefanty AG, Brysha M, Kile BJ, Richardson R, Baca M, Zhang J-G, Willson TA, Viney EM, Sprigg NS, Rakar S, Corbin J, Mifsud S, Di Rago L, Cary D, Nicola NA, Hilton DJ. Suppressors of cytokine signaling (SOCS): negative regulators of signal transduction. *J Leukoc Biol* (in press)
38. Begley CG, Green AR. The SCL gene: from case report to critical hematopoietic regulator. *Blood* 93:2760–2770, 1999
39. Begley CG, Nicola NA. Resolving conflicting signals: cross inhibition of cytokine signaling pathways. *Blood* 93:1443–1447, 1999
40. Gainsford T, Alexander WS. Leptin, a role in hemopoiesis? *Mol Biotechnol* 11:149–158, 1999
41. Gibbs P, Robinson WA. The genes and genetics of malignant melanoma. In: Nicola R, ed. *Malignant melanoma*. (in press)
42. Hilton DJ. Negative regulators of cytokine signal transduction. *Cell Mol Life Sci* (in press)
43. Metcalf D. Cellular hematopoiesis in the twentieth century. *Semin Hematol* (in press)
44. Metcalf D. The nature of hematopoietic cell development as deducible from clonal cultures. In: Zon L, ed. *Hematopoiesis: a developmental approach*. Oxford: Oxford University Press. (in press)
45. Metcalf D. On relevance. *Stem Cells* 17:1–8, 1999
46. Nandurkar HH, Robb L, Begley CG. The role of IL-II in hematopoiesis as revealed by a targeted mutation of its receptor. *Stem Cells* 16 (Suppl 2):53–65, 1998
47. Rasko JEJ, Begley CG. The thrombopoietic factor, Mpl-ligand. *Int J Biochem Cell Biol* 30:657–660, 1998
48. Roberts AW, Foote S, Metcalf D. Genetic approaches to the investigation of the mechanisms of hematopoietic progenitor cell mobilization into the blood. In: Abraham NG, Tabilio A, Asano M, Marteli M, eds. *Molecular Biology of Hematopoiesis 6*. New York: Plenum Press. (in press)
49. Schofield JR, Robinson WA. *Moles and melanoma*. John Hopkins Press. (in press)
50. Scott CL, Begley CG. The beta common chain (βc) of the granulocyte macrophage-colony stimulating factor, interleukin-3 and interleukin-5 receptors. *Int J Biochem Cell Biol* (in press)
51. Starr R. Inhibitors of the JAK/STAT signalling pathway. In: *Cytokine inhibitors*. New York: Marcel Dekker Inc. (in press)
52. Allison J, Strasser A. Mechanisms of β -cell death in diabetes: a minor role for CD95. *Proc Natl Acad Sci U S A* 95:13818–13822, 1998
53. Ekert PG, Silke J, Vaux DL. Inhibition of apoptosis and clonogenic survival of cells expressing crmA variants: optimal caspase substrates are not necessarily optimal inhibitors. *Embo J* 18:330–338, 1999
54. Grell M, Zimmermann G, Gottfried E, Chen C-M, Grünwald U, Huang DCS, Wu Lee Y-H, Dürkop H, Engelmann H, Scheurich P, Wajant W, Strasser A. Induction of cell death by tumor necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF. *Embo J* 18:3034–3043, 1999
55. Hinds MG, Norton RS, Vaux DL, Day CL. Solution structure of a baculovirus inhibitor of apoptosis (IAP) repeat. *Nat Struct Biol* 6:648–651, 1999
56. Holmgren SP, Huang DCS, Adams JM, Cory S. Survival activity of Bcl-2 homologs Bcl-w and A1 only partially correlates with their ability to bind pro-apoptotic family members. *Cell Death Differ* 6:525–532, 1999
57. Moriishi K, Huang DCS, Cory S, Adams JM. Bcl-2 family members do not prevent apoptosis by binding the caspase-activator Apaf-1. *Proc Natl Acad Sci U S A* 96:9683–9696, 1999
58. O'Connor L, Strasser A. Fas, p53 and apoptosis. *Science* 284:1430, 1999
<<http://www.sciencemag.org/cgi/content/full/284/5419/1431b>>
59. O'Reilly LA, Cullen L, Moriishi K, O'Connor L, Huang DCS, Strasser A. Rapid hybridoma screening method for the identification of monoclonal antibodies to low-abundance cytoplasmic proteins. *Biotechniques* 25:824–830, 1998
60. Ogilvy S, Metcalf D, Gibson L, Bath ML, Harris AW, Adams JM. Promoter elements of vav drive transgene expression in vivo throughout the hematopoietic compartment. *Blood* 94:1855–1863, 1999
61. Print CG, Loveland KL, Gibson L, Meehan T, Stylianou A, Wreford N, de Kretser D, Metcalf D, Köntgen F, Adams JM, Cory S. Apoptosis regulator Bcl-w is essential for spermatogenesis but appears otherwise redundant. *Proc Natl Acad Sci U S A* 95:12424–12431, 1998
62. Puthalakath H, Huang DCS, O'Reilly LA, King SM, Strasser A. The pro-apoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex. *Mol Cell* 3:287–296, 1999
63. Strasser A, Grumont RJ, Stanley ML, Gerondakis S. The transcriptional regulator Rel is essential for antigen receptor

Molecular Genetics of Cancer Division

Primary

52. Allison J, Strasser A. Mechanisms of β -cell death in diabetes: a minor role for CD95. *Proc Natl Acad Sci U S A* 95:13818–13822, 1998
53. Ekert PG, Silke J, Vaux DL. Inhibition of apoptosis and clonogenic survival of cells expressing crmA variants: optimal caspase substrates are not necessarily optimal inhibitors. *Embo J* 18:330–338, 1999
54. Grell M, Zimmermann G, Gottfried E, Chen C-M, Grünwald U, Huang DCS, Wu Lee Y-H, Dürkop H, Engelmann H, Scheurich P, Wajant W, Strasser A. Induction of cell death by tumor necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF. *Embo J* 18:3034–3043, 1999
55. Hinds MG, Norton RS, Vaux DL, Day CL. Solution structure of a baculovirus inhibitor of apoptosis (IAP) repeat. *Nat Struct Biol* 6:648–651, 1999
56. Holmgren SP, Huang DCS, Adams JM, Cory S. Survival activity of Bcl-2 homologs Bcl-w and A1 only partially correlates with their ability to bind pro-apoptotic family members. *Cell Death Differ* 6:525–532, 1999
57. Moriishi K, Huang DCS, Cory S, Adams JM. Bcl-2 family members do not prevent apoptosis by binding the caspase-activator Apaf-1. *Proc Natl Acad Sci U S A* 96:9683–9696, 1999
58. O'Connor L, Strasser A. Fas, p53 and apoptosis. *Science* 284:1430, 1999
<<http://www.sciencemag.org/cgi/content/full/284/5419/1431b>>
59. O'Reilly LA, Cullen L, Moriishi K, O'Connor L, Huang DCS, Strasser A. Rapid hybridoma screening method for the identification of monoclonal antibodies to low-abundance cytoplasmic proteins. *Biotechniques* 25:824–830, 1998
60. Ogilvy S, Metcalf D, Gibson L, Bath ML, Harris AW, Adams JM. Promoter elements of vav drive transgene expression in vivo throughout the hematopoietic compartment. *Blood* 94:1855–1863, 1999
61. Print CG, Loveland KL, Gibson L, Meehan T, Stylianou A, Wreford N, de Kretser D, Metcalf D, Köntgen F, Adams JM, Cory S. Apoptosis regulator Bcl-w is essential for spermatogenesis but appears otherwise redundant. *Proc Natl Acad Sci U S A* 95:12424–12431, 1998
62. Puthalakath H, Huang DCS, O'Reilly LA, King SM, Strasser A. The pro-apoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex. *Mol Cell* 3:287–296, 1999
63. Strasser A, Grumont RJ, Stanley ML, Gerondakis S. The transcriptional regulator Rel is essential for antigen receptor

- mediated stimulation of mature T cells but dispensable for positive and negative selection of thymocytes and T cell apoptosis. *Eur J Immunol* 29:928–935, 1999
64. Villunger A, Strasser A. 'The great escape' – how important is tumor immune evasion for neoplastic transformation? *Nature Med* 8:874–875, 1999
 65. Zhang J-G, Farley A, Nicholson SE, Willson TA, Zugaro LM, Simpson RJ, Moritz RL, Cary D, Richardson R, Hausmann G, Kile BJ, Kent SBH, Alexander WS, Metcalf D, Hilton DJ, Nicola NA, Baca M. The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. *Proc Natl Acad Sci U S A* 96:2071–2076, 1999
- ### Reviews and books
66. Adams JM, Harris AW, Strasser A, Ogilvy S, Cory S. Transgenic models of lymphoid neoplasia and development of a pan-hematopoietic vector. *Oncogene* (in press)
 67. Cory S. The Walter and Eliza Hall Institute of Medical Research. *Chiron* 4:30–33, 1999
 68. Cory S. Cell death throes. *Proc Natl Acad Sci U S A* 95:12077–12079, 1998
 69. Cory S, Vaux DL, Strasser A, Harris AW, Adams JM. Insights from Bcl-2 and Myc: malignancy involves abrogation of apoptosis as well as sustained proliferation. *Cancer Res* 59:1685s–1692s, 1999
 70. Fredrickson TN, Harris AW. *Atlas of Mouse Hematopathology*. Amsterdam: Harwood Academic Publishers. (in press)
 71. Hawkins CJ, Coulson EJ, Vaux DL. Baculovirus lessons in apoptosis. In: Watters D and Lavin M, eds. *Signalling pathways in apoptosis*. Amsterdam: Harwood Academic Publishers, 1999
 72. Magnusson C, Vaux DL. Signalling by CD95 and TNF receptors: not only life and death. *Immunol Cell Biol* 77:41–46, 1999
 73. O'Reilly LA, Strasser A. Apoptosis and autoimmune disease. *Inflamm Res* 48:5–21, 1999
 74. Strasser A. Dr. Josef Steiner Cancer Research Prize Lecture: the role of physiological cell death in neoplastic transformation and in anti-cancer therapy. *Int J Cancer* 81:505–511, 1999
 75. Strasser A, Newton K. FADD/MORT 1 a signal transducer that can promote cell death or cell growth. *Int J Biochem Cell Biol* 31:533–537, 1999
 76. Vaux DL. Immunology. Ways around rejection [retraction of Vaux DL. In: *Nature* 1995 Oct 19;377(6550):576–7]. *Nature* 394:133, 1998
 77. Vaux DL, Korsmeyer SJ. Cell death in development. *Cell* 96:245–254, 1999
 78. Verhagen AM, Vaux DL. Molecular mechanisms of apoptosis: an overview. *Results Probl Cell Differ* 23:11–24, 1999
 79. Villunger A, Strasser A. Does 'death receptor' signalling play a role in tumourigenesis and cancer therapy? *Oncol Res* 10:541–550, 1999
 84. Grumont RJ, Rourke II, Gerondakis S. Rel-dependent induction of A1 transcription is required to protect B cells from antigen receptor ligation-induced apoptosis. *Genes Dev* 13:400–411, 1999
 85. Harling-McNabb L, Deliyannis G, Jackson DC, Gerondakis S, Grigoriadis G, Brown LE. Mice lacking the transcription factor subunit Rel can clear an influenza infection and have functional anti-viral cytotoxic T cells but do not develop an optimal antibody response. *Int Immunol* (in press)
 86. Hoglund P, Mintern J, Waltzinger C, Heath WR, Benoist C, Mathis D. Initiation of autoimmune diabetes by developmentally regulated presentation of islet cell antigens in the pancreatic lymph nodes. *J Exp Med* 189:331–339, 1999
 87. Kelly KA, Lucas K, Hochrein H, Metcalf D, Wu L, Shortman K. Development of dendritic cells in cultures from human and murine thymic precursor cells. *Cell Mol Biol* (in press)
 88. Koniaris C, Carbone FR, Heath WR, Lew AM. Inhibition of naive class I-restricted T cells by altered peptide ligands. *Immunol Cell Biol* (in press)
 89. Kurts C, Carbone FR, Krummel MF, Koch KM, Miller JFAP, Heath WR. Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells. *Nature* 398:341–344, 1999
 90. Morgan DJ, Kurts C, Kreuwel HT, Holst KL, Heath WR, Sherman LA. Ontogeny of T cell tolerance to peripherally expressed antigens. *Proc Natl Acad Sci U S A* 96:3854–3858, 1999
 91. Puls KL, Ni J, Liu D, Morahan G, Wright MD. The molecular characterisation of a novel tetraspanin protein, TM4-B. *Biochim Biophys Acta* (in press)
 92. Rolph MS, Matthaei KI, Carbone FR, Heath WR, Ramshaw IA. Loss of antiviral cytotoxic T-lymphocyte activity during high-level antigen stimulation. *Viral Immunol* 11:183–195, 1998
 93. Strasser A, Grumont RJ, Stanley ML, Gerondakis S. The transcriptional regulator Rel is essential for antigen receptor mediated stimulation of mature T cells but dispensable for positive and negative selection of thymocytes and T cell apoptosis. *Eur J Immunol* 29:928–935, 1999
 94. Williams GS, Malin M, Vremec D, Chang CH, Boyd R, Benoist C, Mathis D. Mice lacking the transcription factor CIITA a second look. *Int Immunol* 10:1957–1967, 1998
 95. Wu L, D'Amico A, Winkel KD, Suter M, Lo D, Shortman K. Rel B is essential for the development of myeloid-related CD8 α -dendritic cells but not of lymphoid-related CD8 α + dendritic cells. *Immunity* 9:839–847, 1998

Reviews and books

96. Heath WR. T Lymphocytes. In: Delves PJ and Roitt IM, eds. *Encyclopedia of Immunology*. San Diego: Academic Press; 1998
97. Heath WR, Carbone FR. Cytotoxic T cell activation by cross-priming. *Curr Opin Immunol* (in press)
98. Heath WR, Kurts C, Caminisch I, Carbone FR, Miller JFAP. CD30 prevents T cell responses to non-lymphoid tissues. *Immunol Rev* (in press)
99. Lucas K, Saunders D, Wu L. Derivation of murine dendritic cells from thymic precursors. In: Robinson S and Stagg A, eds. *Methods in molecular medicine series: dendritic cell protocols*. Humana Press. (in press)
100. Maraskovsky E, Pulendran B, Shortman K. Lymphoid-related dendritic cells. In: Lotze MT and Thomson AW, eds. *Dendritic cells: biology and clinical applications*. San Diego: Academic Press; 93–107, 1999
101. Maraskovsky E, Wu L. Dendritic cell development. *Today's Life Sci* 11:62–64, 1999
102. Shortman K, Maraskovsky E. Developmental options. *Science* 282:424–425, 1998
103. Shortman K, Wu L. Thymic dendritic cells. In: Lotze MT and Thomson AW, eds. *Dendritic cells: biology and clinical applications*. San Diego: Academic Press; 15–28, 1999
104. Vandenabeele S, Wu L. Dendritic cell origins: puzzles and paradoxes. *Immunol Cell Biol* (in press)

Infection and Immunity Division

Primary

105. Beeson JC, Brown GV, Molyneux ME, Mhango C, Dzinjalama F, Rogerson SJ. *Plasmodium falciparum* isolates from infected pregnant women and children are each associated with distinct adhesive and antigenic properties. *J Infectious Dis* 180:464–472, 1999
106. Marshall VM, Tiejiao W, Coppel RL. Close linkage of three merozoite surface protein genes on chromosome 2 of *Plasmodium falciparum*. *Mol Biochem Parasitol* 94:13–25, 1998
107. Piani A, Ilg T, Elefanty AG, Curtis J, Handman E. *Leishmania major* proteophosphoglycan is expressed by amastigotes and has an immunomodulatory effect on macrophage function. *Microbes Infect* 2:1–11, 1999
108. Reeder JC, Cowman AF, Davern KM, Beeson JC, Thompson JK, Rogerson SJ, Brown GV. The adhesion of *Plasmodium falciparum* infected erythrocytes to chondroitin sulfate A is mediated by *P. falciparum* erythrocyte membrane protein 1. *Proc Natl Acad Sci U S A* 96:5198–5202, 1999
109. Saul A, Lawrence G, Smillie A, Rzepczyk CM, Reed C, Taylor D, Anderson K, Stowers A, Kemp R, Allworth A, Anders RF, Brown GV, Pye D, Schoofs P, Irving DO, Dyer SL, Woodrow GC, Briggs WRS, Reber R, Sturchler D. Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant. *Vaccine* 17: 3145–3159, 1999
110. Schofield L, McConville MJ, Hansen D, Campbell S, Fraser-Reid B, Grusby MJ, Tachado SD. CD1d-restricted immunoglobulin G formation to GPI-anchored antigens mediated by NKT cells. *Science* 283:225–229, 1999
111. Tachado SD, Mazhari-Tabrizi R, Schofield L. Specificity in signal transduction among glycosylphosphatidylinositols of *Plasmodium falciparum*, *Trypanosoma brucei*, *Trypanosoma cruzi* and *Leishmania* spp. *Parasite Immunol* (in press)
112. Thompson JK, Caruana SR, Cowman AF. Yac contigs and restriction maps of chromosomes 4 and 5 from the cloned line 3D7 of *Plasmodium falciparum*. *Mol Biochem Parasitol* (in press)
113. Triglia T, Cowman AF. *Plasmodium falciparum*: a homologue of p-Aminobenzoic acid synthetase. *Exp Parasitol* 92:154–158, 1999
114. Waller RF, Keeling PJ, Donald RG, Striepen B, Handman E, Lang-Unnasch N, Cowman AF, Besra GS, Roos DS, McFadden GI. Nuclear-encoded proteins target to the plastid in *Toxoplasma gondii* and *Plasmodium falciparum*. *Proc Natl Acad Sci U S A* 95:12352–12357, 1998
115. Waterkeyn JG, Crabb BS, Cowman AF. Transfection of the human malaria parasite *Plasmodium falciparum*. *Int J Parasitol* 29: 945–955, 1999

Reviews and books

116. Biggs BA, Brown GV. Malaria. In: Gillespie S and Pearson R, eds. *Principles and practice of clinical parasitology*. New York: John Wiley & Sons. (in press)
117. Brown GV. Progress in the development of malaria vaccines-context and constraints. *Parassitologia* (in press)
118. Handman E. Cell biology of *Leishmania*. *Adv Parasitol* (in press)
119. Schofield L. Glycosylphosphatidylinositols in lower animals. In: Young N, ed. *Paroxysmal nocturnal hemoglobinuria and the glycosylphosphoinositol linked proteins*. San Diego: Academic Press. (in press)
120. Triglia T. Inverse PCR (IPCR) for obtaining promoter sequence. *Methods Mol Biol* (in press)
121. Triglia T, Cowman AF. The mechanism of resistance to sulfa drugs in *Plasmodium falciparum*. *Drug Resist Updates* 2:15–19, 1998

Autoimmunity and Transplantation Division

Primary

122. Brady JL, Lew AM. Additive efficacy of CTLA4Ig and OX40Ig secreted by genetically modified grafts. *Transplantation* (in press)
123. Chaplin PJ, De Rose R, Boyle JS, McWaters P, Kelly J, Tennent J, Lew AM, Scheerlinck JY. Targeting improves the efficacy of a DNA vaccine against *Corynebacterium pseudotuberculosis* in sheep. *Infect Immun* (in press)
124. Cooley HM, Melny BJ, Gleeson R, Greco T, Kay TWH. Clinical and serological associations of anti-Ku antibody. *J Rheumatol* 26:563–567, 1999
125. Couper JJ, Steele C, Beresford S, Powell T, McCaul K, Pollard A, Gellert S, Tait B, Harrison LC, Colman PG. Lack of association between duration of breast feeding or introduction of cow's milk and development of islet autoimmunity. *Diabetes* (in press)
126. Cram DS, McIntosh A, Oxbrow L, Johnston AM, DeAizpurua HJ. Differential mRNA display analysis of two related but functionally distinct rat insulinoma (RIN) cell lines: identification of CD24 and its expression in the developing pancreas. *Differentiation* 64:237–246, 1999
127. Harrison LC, Honeyman MC. Cow's milk and type 1 diabetes: the real debate is about mucosal immune function. *Diabetes* 48:1501–1507, 1999
128. Honeyman MC, Brusic V, Stone NL, Harrison LC. Neural network-based prediction of candidate T-cell epitopes. *Nat Biotechnol* 16:966–999, 1998
129. Jiang FX, Cram DS, DeAizpurua HJ, Harrison LC. Laminin-1 promotes differentiation of fetal mouse pancreatic beta-cells. *Diabetes* 48:722–730, 1999
130. Koniaris C, Carbone FR, Heath WR, Lew AM. Inhibition of naive class I-restricted T cells by altered peptide ligands. *Immunol Cell Biol* (in press)
131. McColl GJ, Kohasaka H, Szer J, Wicks IP. High dose chemotherapy and syngeneic haemopoietic stem cell transplantation for severe seronegative rheumatoid arthritis. *Ann Intern Med* (in press)
132. Murphy VJ, Harrison LC, Rudert WA, Luppi P, Trucco M, Fierabracci A, Biro PA, Bottazzo GF. Retroviral superantigens and type 1 diabetes mellitus. *Cell* 95:9–11, 1998
133. Myers M, Georgiou HM, Byron S, Degli-Eposti M. Inhibition of mitochondrial oxidative phosphorylation induces hyper-expression of glutamic acid decarboxylase in pancreatic islet cells. *Autoimmunity* 30:43–51, 1999
134. O'Donnell K, Harkes IC, Dougherty L, Wicks IP. Expression of receptor tyrosine kinase Axl and its ligand Gas6 in rheumatoid arthritis: evidence for a novel endothelial cell survival pathway. *Am J Pathol* 154:1171–1180, 1999
135. Rentsch JL, Rosenfeld JV, Wicks IP. An unusual cause of back pain. *Aust Fam Physician* 28:354–355, 1999
136. Stephens LA, Thomas HE, Ming LI, Grell M, Darwiche R, Volodin L, Kay TWH. Tumor necrosis factor- α -activated cell death pathways in NIT-1 insulinoma cells and primary pancreatic β cells. *Endocrinology* 140:3219–3227, 1999
137. Thomas HE, Darwiche R, Corbett JA, Kay TWH. Evidence that β cell death in the nonobese diabetic mouse is fas independent. *J Immunol* 163:1562–1569, 1999
138. Yi S, Feng X, Wang Y, Kay TWH, O'Connell PJ. CD4⁺ cells play a major role in xenogeneic human anti-pig cytotoxicity through the Fas/Fas ligand lytic pathway. *Transplantation* 67:435–443, 1999

Reviews and books

139. Boyle JS, Barr IG, Lew AM. Strategies for improving responses to DNA vaccines. *Mol Med* 5:1–8, 1999

Development and Neurobiology Group

Primary

140. Coleman GJ, Bernard CC, Bernard O. Bcl-2 transgenic mice with increased number of neurons have a greater learning capacity. *Brain Res* 832:188–194, 1999
141. Coulson EJ, Reid K, Barrett GL, Bartlett PF. p75 neurotrophin receptor-mediated neuronal death is promoted by Bcl-2 and prevented by Bcl-x_L. *J Biol Chem* 274:16387–16391, 1999
142. Dowsing BJ, Morrison WA, Nicola NA, Starkey GP, Bucci T, Kilpatrick TJ. Leukemia inhibitory factor is an autocrine survival factor for Schwann cells. *J Neurochem* 73:96–104, 1999
143. Dutton R, Bartlett PF. Precursor cells in the subventricular zone of the adult mouse are actively inhibited from differentiating into neurons. *Dev Neurosci* (in press)
144. Dutton R, Yamada T, Turnley A, Bartlett PF, Murphy M. Sonic hedgehog promotes neuronal differentiation of murine spinal cord precursors and collaborates with neurotrophin 3 to induce Islet-1. *J Neurosci* 19:2601–2608, 1999
145. Dutton R, Yamada T, Turnley AM, Bartlett PF, Murphy M. Regulation of spinal motorneuron differentiation by the combined action of sonic hedgehog and neurotrophin 3. *Clin Exp Pharmacol Physiol* (in press)
146. Epa WR, Rong P, Bartlett PF, Coulson EJ, Barrett GL. Enhanced downregulation of the p75 nerve growth factor receptor by cholesteryl and bis-cholesteryl antisense oligonucleotides. *Antisense Nucleic Acid Drug Dev* 8:489–498, 1998
147. Heaton MB, Moore DB, Paiva M, Gibbs T, Bernard O. Bcl-2 overexpression protects the neonatal cerebellum from ethanol neurotoxicity. *Brain Res* 817:13–18, 1999
148. Koblar SA, Murphy M, Barrett GL, Underhill A, Gros P, Bartlett PF. Pax-3 regulates neurogenesis in neural crest-derived precursor cells. *J Neurosci Res* 56:518–30, 1999
149. Marzella PL, Gillespie LN, Clark GM, Bartlett PF, Kilpatrick TJ. The neurotrophins act synergistically with LIF and members of the TGF β superfamily to promote the survival of spiral ganglia neurons *in vitro*. *Hearing Res* (in press)
150. Murray S, Bartlett PF, Cheema S. Differential loss of spinal sensory but not motor neurons in the p75 knockout mouse. *Neurosci Lett* 267:45–48, 1999
151. Soilu-Hänninen M, Ekert PG, Bucci T, Syroid DE, Bartlett PF, Kilpatrick TJ. Nerve growth factor signaling through p75 induces apoptosis in Schwann cells via a Bcl-2-independent pathway. *J Neurosci* 19:4828–4838, 1999
152. Stanyon CA, Bernard O. LIM-kinase1. *Int J Biochem Cell Biol* 31:389–394, 1999
153. Syroid DE, Zorick TS, Arbet-Engels C, Kilpatrick TJ, Eckhart W, Lemke G. A role for insulin-like growth factor-I in the regulation of Schwann cell survival. *J Neurosci* 19:2059–2068, 1999
154. Turnley AM, Bartlett PF. Nerve growth factor modulates myelin-associated glycoprotein binding to sensory neurons. *Int J Dev Neurosci* 17:109–119, 1999
155. Turnley AM, Stapleton D, Mann RJ, Witters LA, Kemp BE, Bartlett PF. Cellular distribution and developmental expression of AMP-activated protein kinase isoforms in mouse central nervous system. *J Neurochem* 72:1707–1716, 1999

Reviews and books

156. Bartlett PF, Brooker GJF, Faux CH, Turnley AM, Kilpatrick TJ. Neural stem cells: regulation and potential use in neuronal regeneration. In: Saunders NR and Dziegielewska KM, eds. *Degeneration and regeneration in the nervous system*. Amsterdam: Harwood Academic Publishers. (in press)
157. Coulson EJ, Reid K, Bartlett PF. Signalling of neuronal cell death by the p75NTR neurotrophin receptor. *Mol Neurobiol* (in press)

158. Hawkins CJ, Coulson EJ, Vaux DL. Baculovirus lessons in apoptosis. In: Watters D and Lavin M, eds. *Signalling pathways in apoptosis*. Amsterdam: Harwood Academic Publishers, 1999
159. Kilpatrick TJ, Soilu-Hänninen M. Molecular mechanisms regulating motor neuron development and degeneration. *Mol Neurobiol* (in press)
160. Kilpatrick TJ, Soilu-Hänninen M. New treatments for multiple sclerosis. *Aust N Z J Med* (in press)

Genetics and Bioinformatics Group

Primary

161. Allison J, Strasser A. Mechanisms of β -cell death in diabetes: a minor role for CD95. *Proc Natl Acad Sci U S A* 95:13818–13822, 1998
162. Cavanaugh JA, Callen DF, Wilson SR, Stanford PM, Sraml ME, Gorska M, Crawford J, Whitmore SA, Shlegel C, Foote S, Kohonen-Corish M, Pavli P. Analysis of Australian Crohn's disease pedigrees refines the localization of susceptibility to inflammatory bowel disease on chromosome 16. *Ann Hum Genet* 62:291–298, 1998
163. Chataway TK, Whittle AM, Lewis MD, Bindloss CA, Davey RC, Moritz RL, Simpson RJ, Hopwood JJ, Meikle PJ. Two-dimensional mapping and microsequencing of lysosomal proteins from human placenta. *Placenta* 19:643–654, 1998
164. Cole AR, Hall NE, Treutlein HR, Eddes JS, Reid GE, Moritz RL, Simpson RJ. Disulfide bond structure and N-glycosylation sites of the extracellular domain of the human interleukin-6 receptor. *J Biol Chem* 274:7207–7215, 1999
165. Hardy CL, Morahan G, Bhathal PS. Immune responses to bile duct implants: effect of transgene expression in hepatocytes. *Liver* (in press)
166. He H, Watanabe T, Zhan X, Huang C, Schuurings E, Fukami K, Takenawa T, Kumar CC, Simpson RJ, Maruta H. Role of phosphatidylinositol 4,5-bisphosphate in Ras/Rac-induced disruption of the cortactin-actomyosin II complex and malignant transformation. *Mol Cell Biol* 18:3829–3837, 1998
167. Lah M, Brodnicki T, Maccarone P, Nash A, Stanley E, Harvey RP. Human cerberus related gene CER1 maps to chromosome 9. *Genomics* 55:364–366, 1999
168. Moritz RL, Ward LD, Tu G, Fabri LJ, Ji H, Yasukawa K, Simpson RJ. The N terminus of gp130 is critical for the formation of the high affinity interleukin-6 receptor complex. *Growth Factors* (in press)
169. Moss JM, Reid GE, Mullin KA, Zawadzki JL, Simpson RJ, McConville MJ. Characterization of a novel GDP-mannose:Serine-protein mannose-1-phosphotransferase from *Leishmania mexicana*. *J Biol Chem* 274:6678–6688, 1999
170. Novak U, Ji H, Kanagasundaram V, Simpson RJ, Paradiso L. STAT3 forms stable homodimers in the presence of divalent cations prior to activation. *Biochem Biophys Res Commun* 247:558–563, 1998
171. Puls KL, Ni J, Liu D, Morahan G, Wright MD. The molecular characterisation of a novel tetraspanin protein, TM4-B. *Biochim Biophys Acta* (in press)
172. Rasmussen RK, Rusak J, Price J, Robinson PJ, Simpson RJ, Dorow DS. Mixed-lineage kinase 2-SH3 domain binds dynamin and greatly enhances activation of GTPase by phospholipid. *Biochem J* 335:119–124, 1998
173. Robb L, Brodnicki T, Copeland NG, Gilbert DJ, Jenkins NA, Harvey RP. Assignment of the human helix-loop-helix transcription factor gene musculin/activated B-cell factor-1 (MSC) to chromosome 8q21 and its mouse homologue (Msc) to the proximal region of chromosome 1. *Genomics* 57:318–319, 1999
174. Swift S, Blackburn C, Morahan G, Ashworth A. Structure and chromosomal mapping of the TNF-alpha inducible endothelial

protein 1 (Edp1) gene in the mouse. *Biochim Biophys Acta* 1442:394–398, 1998

175. Zhang J-G, Farley A, Nicholson SE, Willson TA, Zugaro LM, Simpson RJ, Moritz RL, Cary D, Richardson R, Hausmann G, Kile BJ, Kent SBH, Alexander WS, Metcalf D, Hilton DJ, Nicola NA, Baca M. The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. *Proc Natl Acad Sci U S A* 96:2071–2076, 1999

Reviews and books

176. Burt RA. Genetics of host response to malaria. *Int J Parasitol* (in press)
177. Foote S. Mediating immunity to mycobacteria. *Nat Genet* 21:345–346, 1999
178. Ji H, Simpson RJ. Nonreducing 2-D polyacrylamide gel electrophoresis. In: Link AJ, ed. *2-D Proteome Analysis Protocols*. Totowa, NJ: Humana Press; 255–263, 1998
179. Morahan G. Burnet – the Bradman of medical research. *Aust Soc Immunol News* (in press)
180. Morahan G. Editorial: understanding the complex genetics of the impact of the immune system on the gastrointestinal system. *Nutrition* (in press)
181. Moritz RL, Simpson RJ. Interleukins. In: Creighton TE, ed. *Encyclopedia of Molecular Biology*. New York: Wiley. (in press)
182. Roberts AW, Foote S, Metcalf D. Genetic approaches to the investigation of the mechanisms of hematopoietic progenitor cell mobilization into the blood. In: Abraham NG, Tabilio A, Asano M and Marteli M, eds. *Molecular Biology of Hematopoiesis 6*. New York: Plenum Press. (in press)

Advanced Technologies

Primary

183. Elefanty AG, Begley CG, Metcalf D, Barnett L, Köntgen F, Robb L. Characterization of hematopoietic progenitor cells that express the transcription factor SCL, using a lacZ “knock-in” strategy. *Proc Natl Acad Sci U S A* 95:11897–11902, 1998
184. Murphy MA, Schnall RG, Venter DJ, Barnett L, Bertonecello I, Thien CB, Langdon WY, Bowtell DD. Tissue hyperplasia and enhanced T-cell signalling via ZAP-70 in c-Cbl- deficient mice. *Mol Cell Biol* 18:4872–4882, 1998
185. Print CG, Loveland KL, Gibson L, Meehan T, Stylianou A, Wreford N, de Kretser D, Metcalf D, Köntgen F, Adams JM, Cory S. Apoptosis regulator bcl-w is essential for spermatogenesis but appears otherwise redundant. *Proc Natl Acad Sci U S A* 95:12424–12431, 1998

Patents Granted

• A Method for Regulating Neuron Development and Maintenance

Inventors: Perry Francis Bartlett, Mark Murphy
Hong Kong HK1002697 (granted 1998)

• A Method for the Diagnosis and Treatment of Insulin Dependent Diabetes Mellitus

Inventors: Leonard Harrison, David Cram, Margo Honeyman
United States 5837812 (granted 1998)

• Monoclonal Antibody

Inventors: Nicos Anthony Nicola, Andrew Wallace Boyd, Kaye Wycherley, Judith Eleanor Layton, Donald Metcalf
Europe 668923 (granted 1999)

• A Method for Enhancing Neuron Survival and Reagents Useful for Same

Inventor: Graham Leslie Barrett
United States 5837694 (granted 1998)

• Immunoreactive and Immunotherapeutic Molecules

Inventors: George Rudy, Leonard Harrison, Andrew Lew, Margo Honeyman
Australia 706774 (granted 1999)

• Primary Biliary Cirrhosis Autoantigen

Inventors: Ross Leon Coppel, Merrill Eric Gershwin
Japan 2815582 (granted 1998), 2875226 (granted 1999)
United States 5891436 (granted 1999)

• In Vitro Propagation of Embryonic Stem Cells

Inventors: Nicholas Martin Gough, Douglas James Hilton, Robert Lindsay Williams
Europe 0380646 (granted 1999)

• Amplified DNA Assay

Inventors: David James Kemp, Simon James Foote, Michael Gregory Peterson, Nicholas Samaras, Donald Bruce Smith
Europe 0447464 (granted 1998)

• Antigens of Plasmodium falciparum

Inventors: Robin Anders, Graham Brown, Ross Coppel, David Kemp, Robert Saint, Alan Cowman, Edward Bianco and Graham Mitchell
Canada 1340213 (granted 1998)

In addition, four provisional patent applications proceeded to the international application stage during the year; provisional patent applications for eleven new inventions were also filed.